Growth • Grifols
GRFS
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
8%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
-5,8%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
-37%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
-36,5%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-30,4%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
-22,3%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!